Minerva Neurosciences Inc
Company Profile
Business description
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
Contact
1500 District Avenue
BurlingtonMA01803
USAT: +1 617 600-7373
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
8
Stocks News & Analysis
stocks
The best way to get rich and retire early
stocks
Investors overly negative on cheap ASX share
stocks
Overvalued US AI play reports earnings
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,096.20 | 77.60 | 0.86% |
| CAC 40 | 8,108.82 | 12.25 | -0.15% |
| DAX 40 | 24,322.69 | 38.72 | 0.16% |
| Dow JONES (US) | 48,355.34 | 7.34 | -0.02% |
| FTSE 100 | 9,889.93 | 23.96 | 0.24% |
| HKSE | 25,774.14 | 27.63 | -0.11% |
| NASDAQ | 23,406.46 | 22.37 | -0.10% |
| Nikkei 225 | 50,412.87 | 10.48 | 0.02% |
| NZX 50 Index | 13,517.73 | 9.43 | 0.07% |
| S&P 500 | 6,878.13 | 0.36 | -0.01% |
| S&P/ASX 200 | 8,795.70 | 78.80 | 0.90% |
| SSE Composite Index | 3,919.98 | 2.61 | 0.07% |